AI assistant
Sending…
ENDRA Life Sciences Inc. — Proxy Solicitation & Information Statement 2023
May 24, 2023
35444_rns_2023-05-24_7734b8ba-8c3b-44de-a123-b4bb1fc8bc14.zip
Proxy Solicitation & Information Statement
Open in viewerOpens in your device viewer
DEFA14A 1 ndra_defa14a.htm DEFA14A ndra_8k.htm Document created using EDGARMaster
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. )
| Filed by the Registrant ☒ | |
|---|---|
| Filed by a Party other than the Registrant ☐ | |
| Check the appropriate box: | |
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement |
| ☒ | Definitive Additional Materials |
| ☐ | Soliciting Material Pursuant to Rule 14a-12 |
| ENDRA LIFE SCIENCES INC. |
|---|
| (Name of Registrant as Specified in its Charter) |
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ | No fee required. |
|---|---|
| ☐ | Fee paid previously with preliminary materials. |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
2
3
More from ENDRA Life Sciences Inc.
Regulatory Filings
2026
May 28
Share Issue/Capital Change
2026
May 15
Interim / Quarterly Report
2026
May 15
Delisting Announcement
2026
Apr 21
Annual Report
2026
Mar 31
Earnings Release
2026
Mar 31
Regulatory Filings
2026
Mar 25
Director's Dealing
2026
Jan 23
Director's Dealing
2026
Jan 23
Director's Dealing
2026
Jan 23